Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Acadia Pharmaceuticals Inc

NASDAQ: ACAD · Life Sciences · 7 alerts · CIK 1070494

Share price
$18.67Close, Nov 16
Market cap
$3.23B
Shares outstanding
172.83MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Acadia Pharmaceuticals Inc filings on SEC EDGAR ↗

6:02 AM ET 10-Q
Financial Results ▶ Call

Acadia Pharmaceuticals Q3 2026 Results: Net Income $53.5M, Down 25.4% YoY

ACADIA Pharmaceuticals reported strong revenue growth driven by its commercial products, NUPLAZID and DAYBUE, alongside disciplined management of operating expenses. The company continues to invest in its late-stage clinical pipeline while showing significant progress toward sustained profitability.

Key figure
Net income $53.5M · -25.4% YoY
4:14 PM ET 8-K
Financial Results

Acadia Pharmaceuticals Financial Results

Acadia Pharmaceuticals reported Q3 2026 total revenues of $342 million, a 22% increase year-over-year, driven by strong sales of DAYBUE and NUPLAZID. The company raised its 2026 net sales guidance for DAYBUE to $505–$520 million and highlighted upcoming Phase 2 readouts for its pipeline candidates in 2027.

Term
Q3 2026

“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID. In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build momentum following our recent launch of DAYBU in Germany. NUPLAZID also performed well, driven by underlying demand and the continued expansion of our commercial reach.”

Catherine Owen Adams, Chief Executive Officer of Acadia
8:21 PM ET Form 4
Insider Selling

Acadia Pharmaceuticals EVP, CFO Mark C. Schneyer Sells $69.3K of Stock

Mark C. Schneyer, EVP, CFO, sold 3,321 shares of Acadia Pharmaceuticals Inc at $20.88 a share, worth $69.3K in total on Oct 30, 2026. Shares held after the trade: 71,322 (-4.4%).

Value
$69.3K
Shares
3,321
Price
$20.88
Role
EVP, CFO
Holding change
-4.4%
Trade date
Oct 30, 2026
4:53 PM ET 8-K
Leadership Change

Acadia Pharmaceuticals Leadership Change

Elizabeth H.Z. Thompson, Ph.D., has stepped down from her role as Executive Vice President and Head of Research and Development at Acadia Pharmaceuticals effective October 23, 2026. Dr. Thompson will transition to a consulting role through December 31, 2026, while the company continues its search for a permanent replacement.

Term
through Dec 2026
5:11 PM ET 8-K
Clinical Trial Data

Acadia Pharmaceuticals Clinical Trial Data

Acadia Pharmaceuticals announced Phase 3 enabling topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer’s disease psychosis (ADP). While the 60 mg dose narrowly missed the primary endpoint (p=0.0603), it showed nominal significance on a key secondary endpoint and a favorable safety profile, leading the company to continue its Phase 3 program with the 60 mg dose.

Earnings call
Sep 24, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.